To evaluate the safety and efficacy of CELZ-201 (Olastrocel) in patients with chronic lower back pain associated with degenerative disc disease, as stated by Creative Medical Technology Holdings, Inc.
Approach:
Key Findings:
Interim results demonstrated significant improvements in pain and functional disability, as reported by Creative Medical Technology Holdings, Inc.
No significant adverse events were reported by the independent Data Safety Monitoring Board, according to the company.
Olastrocel is an allogeneic, perinatal tissue-derived regenerative cell therapy administered through a minimally invasive procedure, as described by Creative Medical Technology Holdings, Inc.
Interpretation:
The expansion cohort aims to further characterize Olastrocel's safety and efficacy in patients with ongoing opioid use.
Limitations:
The article does not provide detailed information on the original ADAPT study population.
Long-term outcomes and broader implications of the therapy are not yet established.
Conclusion:
The expansion of the ADAPT trial is a step towards evaluating Olastrocel's potential in a larger patient population.
